Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P635 Superior outcomes with early biologic-combination treatment in Crohn’s Disease: Data from an international inception cohort

ECCO'20 Vienna

Year: 2020
Authors:

M. Matheeuwsen1, K. Vermeijden1, P. Bossuyt2, L. Pouillon2, F. Baert3, N. de Boer4, M. Duijvestein4, M. Löwenberg1, C. Ponsioen1, W. Bemelman5, G. D’Haens1, K. Gecse1

1Amsterdam UMC- Academic Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, 2Imelda GI Clinical Research Center, Department of Gastroenterology, Bonheiden, Belgium, 3AZ Delta hospital, Department of Gastroenterology, Roeselare, Belgium, 4Amsterdam UMC- VU University Medical Center- AGandM Research Institute, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, 5Amsterdam UMC- Academic Medical Center, Department of Surgery, Amsterdam, The Netherlands

P636 Changes in peripheral helper T-cell was associated with sustained response to a 12-week EEN therapy in active Crohn’s disease: A pilot study

ECCO'20 Vienna

Year: 2020
Authors:

K. Guo1,2, W. Gong3, T. Zheng4, W. Li1, M. Fang4, H. Xie4, G. Wang4, G. Gu4

1Department of General Surgery, Medical School of Nanjing University, Nanjing, China, 2The First Affiliated Hospital of USTC, Department of General Surgery, Hefei, China, 3Department of General Surgery, School of Medicine, Southeast University, Nanjing, China, 4Department of General Surgery, Jinling Hospital, Nanjing Medical University, Nanjing, China

P637 PERFUSE: A french non-interventional cohort study of infliximab-naive and transitioned patients receiving infliximab biosimilar SB2; An interim analysis

ECCO'20 Vienna

Year: 2020
Authors:

Y. Bouhnik1, B. Fautrel2, G. Desjeux3, U. Freudensprung4, A. Brigui5, J. Addison6

1Beaujon Hospital, Department of Gastroenterology- AP-HP- Paris Diderot University, Clichy, France, 2Pitié-Salpêtrière Hospital, Department of Rheumatology- AP-HP- Sorbonne University- UPMC university, Paris, France, 3E-health Services Sanoïa, Digital CRO, Gémenos, France, 4Biogen International GmbH, n/a, Zug, Switzerland, 5Biogen France SAS, n/a, Paris, France, 6Biogen UK, n/a, Maidenhead, UK

P638 Stenotic Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

W. El Ouardi, L. Nawal, B. Imane, B. Camelia, B. Mohamed, A. Fatima Zahra

Ibn Sina University Hospital Mohamed V University- Souissi- Rabat, Medicine C, Rabat, Morocco

P639 Outcomes of a clinical psychology intervention in a UK IBD service

ECCO'20 Vienna

Year: 2020
Authors:

F. Eldridge DClin Psyc, K. Strongili, M. Parkes, T. Raine

Addenbrooke’s Hospital, Dept of Gastroenterology, Cambridge, UK

P640 Moderate to severe endoscopic inflammation is frequent after clinical remission in pediatric ulcerative colitis: A cause for disease extension and relapse?

ECCO'20 Vienna

Year: 2020
Authors:

C. Sarbagili Shabat1,2, D. Weiner1, J. Wardi3, L. Abramas1, M. Yaakov1, A. Levine1,2

1The E. Wolfson Medical Center, Pediatric and Gastroenterology and nutrition unit, Holon, Israel, 2Tel-Aviv University, The Sackler Faculty of Medicine, Tel-Aviv, Israel, 3The E. Wolfson Medical Center, Gastroenterology, Holon, Israel

P641 An increased baseline mucosal TNF burden linked to adalimumab non-response: opportunities for therapeutic drug monitoring

ECCO'20 Vienna

Year: 2020
Authors:

B. Verstockt1, J. Stylli2, P. Rahimian2, A. Rajulapati2, K. Ehring2, D. Thomas3, J. Sabino1, M. Ferrante1, S. Singh2, S. Vermeire1

1IBD Leuven, 1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2Progenity Inc., Progenity Inc., San Diego California, USA, 3KU Leuven, Laboratory for Therapeutic and Diagnostic Antibodies- Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium

P642 Serum adalimumab levels measured between days 9 and 13 from drug injection can be interpreted clinically in a similar way to trough levels in patients with inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

J. Guardiola Capón1, K. Serra1, L. Rodríguez-Alonso1, E. Santacana2, N. Padullés2, A. Ruiz-Cerulla1, C. Arajol1, B. Camps1, G. Surís1, E. Sanchez1, F. Rodríguez-Moranta1

1Hospital Universitari de Bellvitge, Gastroenterology, Barcelona, Spain, 2Hospital Universitari de Bellvitge, Pharmacy, Barcelona, Spain

P643 Development of quantitative ultrasonographic activity score in ileal Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

M. Livne Margolin1, M. Amitai2, E. Klung2, B. Ungar1, R. Eliakim1, S. Ben-Horin1, D. Carter1, U. Kopylov1

1Department of Gastroenterology, Sheba Medical Center, Ramat Gan, Israel, 2Department of Diagnostic Imaging, Sheba Medical Center, Ramat Gan, Israel

P644 Post-operative Crohn’s disease recurrence in Glasgow: How common is it and does deprivation matter?

ECCO'20 Vienna

Year: 2020
Authors:

E. Brownson1, S. Shields1, M.H. Derakhshan1, J. Macdonald1, G. Nicholson2, J.P. Seenan1

1Queen Elizabeth University Hospital, Department of Gastroenterology, Glasgow, UK, 2Queen Elizabeth University Hospital, Department of Surgery, Glasgow, UK

P645 Adalimumab drug monitoring is superior to empirical treatment adjustment in inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

P. CURRAIS1, S. Fernandes2, S. Bernardo2, L. Correia2, A.R. Gonçalves2, C. Baldaia2, P. Moura Santos2, A. Valente2, R. Tato Marinho2

1Instituto Português de Oncologia de Lisboa, Gastrenterologia, Lisboa, Portugal, 2Hospital de Santa Maria, Gastrenterologia, Lisboa, Portugal

P646 Utilisation of indocyanine green fluorescence imaging for Crohn’s disease following intestinal resection

ECCO'20 Vienna

Year: 2020
Authors:

Y. Duan, Y. Li

Shanghai Ninth People’s Hospital- Shanghai Jiao Tong University School of Medicine Department of general surgery, Shanghai Ninth People’s Hospital- Shanghai Jiao Tong University School of Medicine, Department of general surgery, shanghai, China

P647 Post-marketing evaluation of reported adverse events of a multi-strain probiotic product confirms that change in manufacturing site had no impact on safety profile

ECCO'20 Vienna

Year: 2020
Authors:

V. Panetta1, I. Simonelli1, A. Bacchieri2, S. Papetti3, E. De Stefani3, S. Colombo4

1L’altrastatistica Srl, for GB Pharma Services and Consulting S.r.l, Rome, Italy, 2Clinical Research and Development Consultants, S.r.l., Sesto Fiorentino, Italy, 3GB Pharma Services and Consulting, S.r.l., Pavia, Italy, 4Beingpharma, S.r.l, Milano, Italy

P648 Efficacy including rapid response and safety of tofacitinib in Japanese patients with ulcerative colitis: A preliminary investigation in a specialised IBD centre

ECCO'20 Vienna

Year: 2020
Authors:

K. WatanabeAssistant Professor1, M. Kawai2, R. Koshiba2, K. Fujimoto2, K. Kojima2, K. Kaku2, N. Kinoshita2, T. Sato1, K. Kamikozuru2, Y. Yokoyama2, T. Miyazaki2, N. Hida2, S. Nakamura2

1Hyogo College of Medicine, Department of Intestinal Inflammation Research, Hyogo, Japan, 2Hyogo College of Medicine, Division of Internal Medicine- Department of Inflammatory Bowel Disease, Hyogo, Japan

P649 Dietary habits in patients with inactive Crohn’s disease: Results of a controlled study

ECCO'20 Vienna

Year: 2020
Authors:

N. Ben Mustapha, H. Ben Youssef, A. Labidi, M. Hafi, M. Fekih, M. Serghini, J. Boubaker

La Rabta Hospital Tunis El Manar University, Department of Gastroenterology A, Tunis, Tunisia

P650 Outcomes of endoscopic balloon dilation for luminal strictures in Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

R. Sarraj, M. Martinho, F. Bravo, E. Benz, P. Juillerat

Inselspital Bern, Gastroenterology- Clinical for Visceral Surgery and Medicine, Bern, Switzerland

P651 Does ambient temperature alter faecal calprotectin levels?

ECCO'20 Vienna

Year: 2020
Authors:

S. Cauchi1, J. Schembri2, M. Muscat2, P. Ellul2

1Mater Dei Hospital- Malta, Department of Medicine, Kirkop, Malta, 2Mater Dei Hospital- Malta, Department of Gastroenterology, Msida, Malta

P652 Underweight patients with Crohn’s disease and without vitamin D supplementation are at high risk of vitamin D deficiency

ECCO'20 Vienna

Year: 2020
Authors:

D. Vranesic Bender1, V. Domislović2, M. Brinar2,3, D. Ljubas Kelečić1, I. Karas1, M. Novosel3, M. Matašin3, Ž. Krznarić1,2,3

1Unit for Clinical Nutrition, Department of Gastroenterology and Hepatology, Zagreb, Croatia, 2Clinical Hospital Centre Zagreb, Department of Gastroenterology and Hepatology, Zagreb, Croatia, 3Zagreb School of Medicine, University of Zagreb, Zagreb, Croatia

P653 Efficacy and safety of an additional 8 weeks of tofacitinib induction therapy: Updated results of the OCTAVE Open study for tofacitinib 8-week induction non-responders

ECCO'20 Vienna

Year: 2020
Authors:

D.T. Rubin1, M.C. Dubinsky2, S. Danese3, R. Saad-Hossne4, D. Ponce de Leon5, E. Maller6, N. Lawendy6, K. Kwok7, C. Su6

1Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, Illinois, USA, 2Department of Pediatrics and Medicine- Icahn School of Medicine at Mount Sinai, New York, New York, USA, 3IBD Center- Department of Gastroenterology- Humanitas Research Hospital, Rozzano, Milan, Italy, 4IBD Group- Botucatu Medical School- São Paulo State University, São Paulo, Brazil, Brazil, 5Pfizer Inc., Lima, Peru, Peru, 6Pfizer Inc., Collegeville, Pennsylvania, USA, 7Pfizer Inc., New York, New York, USA

P654 Influence of the interval of time between anti-TNF and vedolizumab or ustekinumab in the response to treatment in patients with inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

I. Bastón Rey1, M. Costa1, C. Calviño-Suarez1, V. Mauriz-Barreiro1, D. De la Iglesia1, J. Gonzalez2, R. Ferreiro-Iglesias1, J.E. Dominguez- Munoz1, M. Barreiro-de Acosta1

1University Hospital Santiago De Compostela CHUS, Department of Gastroenterology- IBD Unit, Santiago De Compostela, Spain, 2University Hospital Santiago De Compostela CHUS, Department of Pharmacy, Santiago De Compostela, Spain